97270 ⎘
Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation
Human cytomegalovirus neutralizing antibodies and use thereof
#902Anti-HER2 glycoantibodies and uses thereof
#903Human PAC1 antibodies
#904HUMANIZED ANTI-EBOLA VIRUS GLYCOPROTEIN ANTIBODIES AND METHODS OF USE
#905Homogenous antibody drug conjugates via enzymatic methods
#906Homogenous antibody drug conjugates via enzymatic methods
#907Method for preparing antibodies having improved properties
#908COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
#909Targeted immunotolerance
#910Thrombin-binding antibody molecules and uses thereof
#911Complement factor D antagonist antibodies and conjugates thereof
#912Sialylated glycoproteins
#913Bispecific antibodies specifically binding to PD1 and LAG3
#914Anti-nodal antibodies and methods of using same
#915Interleukin-2 muteins for the expansion of T-regulatory cells
#916ANTI-IL-17A AND IL-17F CROSS REACTIVE ANTIBODY VARIANTS AND COMPOSITIONS COMPRISING AND METHODS OF MAKING AND USING SAME
#917Nucleic acid encoding dual Fc antigen binding proteins
#918ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#919Sialylated Glycoproteins
#920Methods for producing fabs and bi-specific antibodies
#921GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
#922Methods for glycoprotein remodeling using endoglycosidase mutants
#923Combination therapy for the treatment of cancer
#924Antibodies against TIM3 and uses thereof
#925GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
#926Anti-nodal antibodies and methods of using same
#927Humanized monoclonal advanced glycation end-product antibody
#928HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#929ANTIBODY FORMULATION
#930TRANSGLUTAMINASE VARIANTS HAVING INCREASED SPECIFIC ACTIVITY
#931Bispecific antigen-binding constructs targeting Her2
#932ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#933OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY
#934HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
#935Anti-C5a antibodies
#936COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY
#937SEPARATION METHOD FOR FUCOSYLATED ANTIBODIES
#938T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
#939ANTIBODIES AGAINST IL-1 BETA
#940Optimized crosslinkers for trapping a target on a substrate
#941Methods of preventing and removing trisulfide bonds
#942Methods of making fucosylated and afucosylated forms of a protein
#943Expression of modified glycoproteins and glycopeptides
#944Anti-BAFFR antibody therapeutic formulations
#945Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase
#946CD73 blockade
#947Interleukin-2 muteins for the expansion of T-regulatory cells
#948Antibody formulations and methods
#949METHOD FOR INCREASING THE GALACTOSE CONTENT OF RECOMBINANT PROTEINS
#950Antibody neutralizing human respiratory syncytial virus
#951Antibody neutralizing human respiratory syncytial virus
#952Antibody neutralizing human respiratory syncytial virus
#953Endos mutant enzyme
#954OPTIMIZED Fc VARIANTS
#955Anti-CD83 antibodies and use thereof
#956Antibodies to IL-6 and use thereof
#957In vivo Imaging using Anti-IL-6 Antibodies
#958COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
#959Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
#960Antibodies to IL-6 and use thereof
#961Immunoglobulin constant region Fc receptor binding agents
#962Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
#963ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES
#964Bispecific antigen-binding constructs targeting HER2
#965Anti-inflammatory polypeptides
#966Methods and compositions for treating fibrotic diseases
#967FcRn antagonists and methods of use
#968Afucosylated protein, cell expressing said protein and associated methods
#969Therapeutic CD47 antibodies
#970CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
#971IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS
#972Manganese supplementation for control of glycosylation in mammalian cell culture process
#973Method for treating pulmonary hypertension with interleukin-5 receptor antibody
#974Anti-human-HER3 antibodies and uses thereof
#975Application and uses of PRG4 and therapeutic modulation thereof
#976Methods of glycoprotein analysis
#977METHODS AND KITS FOR CANCER ANTIGEN AND HEPARAN SULFATE IMAGING
#978OPTIMIZED ANTIBODIES THAT TARGET CD19
#979T cell receptor-like antibodies specific for a PRAME peptide
#980ANTIGEN BINDING PROTEINS
#981Surface anchored light chain bait antibody display system
#982ANTI-LAMP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES, AND USES THEREOF
#983Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
#984OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION
#985Human monoclonal antibodies specific for glypican-3 and use thereof
#986Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
#987Anti-transferrin receptor antibodies and methods of use
#988Cancer cell specific anti-podocalyxin antibody and method for producing same
#989Antibody-drug conjugates
#990COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE
#991Methods and compositions for treatment of symptoms associated with intracranial hemorrhage
#992Optimized nucleic acid sequences coding for the alpha-chain of human chorionic gonadotropin
#993ANTI-INFLAMMATORY AGENTS
#994Expression of modified glycoproteins and glycopeptides
#995Antibodies specific to glycosylated PD-L1 and methods of use thereof
#996Bispecific multivalent fusion proteins
#997Immune complex
#998Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1
#999Methods of treating autoimmunity using specific anti-IL-6 antibodies
#1000Fc containing polypeptides with altered glycosylation and reduced effector function
#1001Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
#1002Human PAC1 antibodies
#1003Method of treating allergic asthma with antibodies to IL-6
#1004Methods for controlling fucosylation levels in proteins
#1005Anti-CD27 antibodies
#1006Human cytomegalovirus neutralizing antibodies and use thereof
#1007ANTI-CEA ANTIBODIES
#1008METHOD OF INHIBITION OF LEUKEMIC STEM CELLS
#1009ANTI-IL-17A AND IL-17F CROSS REACTIVE ANTIBODY VARIANTS AND COMPOSITIONS COMPRISING AND METHODS OF MAKING AND USING SAME
#1010Polyomavirus neutralizing antibodies
#1011Endoglycosidase mutants for glycoprotein remodeling and methods of using it
#1012Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
#1013Multivalent and multiepitopic antibodies having agonistic activity and methods of use
#1014MASKED ANTI-CD3 ANTIBODIES AND METHODS OF USE
#1015Anti-Tim-3 antibodies
#1016Multispecific antibodies facilitating selective light chain pairing
#1017ANTIBODY AND PROTEIN FORMULATIONS
#1018Anti-inflammatory polypeptides
#1019Lysine conjugated immunoglobulins
#1020Glycosylated immunoglobulin single variable domains
#1021Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof
#1022Antagonists of IL-6 to raise albumin and/or lower CRP
#1023PERTUZUMAB VARIANTS AND EVALUATION THEREOF
#1024PERTUZUMAB VARIANTS AND EVALUATION THEREOF
#1025Pertuzumab variants and evaluation thereof
#1026Fc mutants with modified functional activity
#1027GLYCOOPTIMIZED ANTIBODY DRUG CONJUGATES
#1028ANTIBODY AND PROTEIN FORMULATIONS
#1029Bispecific anti-HER2 antibody
#1030Bispecific binding proteins and uses thereof
#1031Isolated host cells expressing anti-IL-6 antibodies
#1032Antibodies against TIM3 and uses thereof
#1033FcRn antibodies and methods of use thereof
#1034Optimized antibodies that target CD19
#1035Anti-CD73 antibodies
#1036Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
#1037METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
#1038Monoclonal antibodies with enhanced ADCC function
#1039Anti-transferrin receptor antibodies and methods of use
#1040Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies
#1041Human Anti-Tau Antibodies
#1042AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
#1043BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
#1044Hyperglycosylated binding polypeptides
#1045Antibodies to CD70
#1046MONOMERIC FC DOMAINS
#1047THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING SAME
#1048HUMAN ANTI-TAU ANTIBODIES
#1049Process for manipulating the level of glycan content of a glycoprotein
#1050LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS
#1051Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
#1052Glycan-based antibody-drug conjugates
#1053HUMANIZED ANTI-ALPHA V BETA 5 ANTIBODIES AND USES THEREOF
#1054Heterodimer protein composition
#1055POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#1056DIAGNOSING AND TREATING IGA NEPHROPATHY
#1057METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING SUGARS
#1058Modified glycoproteins
#1059Anti-Axl antagonistic antibodies
#1060IMMUNOGLOBULINS WITH REDUCED AGGREGATION
#1061Method of using insulin for controlling glycosylation of recombinant glycoprotein
#1062Antibody binding to carbonic anhydrase and use thereof
#1063FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES
#1064Antagonists of IL-6 to raise albumin and/or lower CRP
#1065Human cytomegalovirus neutralizing antibodies and use thereof
#1066Catheter package including catheter straightening means
#1067Dosage and administration of non-fucosylated anti-CD40 antibodies
#1068Copper supplementation for control of glycosylation in mammalian cell culture process
#1069Anti-NGF compositions and use thereof
#1070GLYCOSYLATION MUTANTS FOR PRODUCING GALACTOSE-FREE AND FUCOSE-FREE POLYPEPTIDES
#1071Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#1072METHODS OF DIAGNOSIS AND TREATMENT OF TUBERCULOSIS AND INFECTION
#1073Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides
#1074COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE
#1075GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS
#1076METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING DISSOLVED OXYGEN
#1077Cell culture medium
#1078Aqueous composition
#1079Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
#1080Bispecific HER2 antibodies
#1081Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection
#1082Protease deficient filamentous fungal cells and methods of use thereof
#1083Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
#1084COMBINED THERAPEUTIC USE OF ANTIBODIES AND ENDOGLYCOSIDASES
#1085Site-specific antibody-drug conjugation through glycoengineering
#1086Anti-EGFR antibody and uses of same
#1087Anti-LAG3 antibodies and antigen-binding fragments
#1088Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
#1089Antibodies that Bind to OX40 and Their Uses
#1090METHOD FOR PRODUCING VARIANTS HAVING AN FC WITH IMPROVED SIALYLATION
#1091GALACTOENGINEERED IMMUNOGLOBULIN 1 ANTIBODIES
#1092Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
#1093Methods of preventing and removing trisulfide bonds
#1094Human PAC1 antibodies
#1095Modified glycoproteins
#1096METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES
#1097Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
#1098METHODS OF CELL CULTURE
#1099Heterodimeric antibody Fc-containing proteins and methods for production thereof
#1100BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
#1101Process for the modification of a glycoprotein using a β-(1,4)-N-acetylgalactosaminyl transferase or a mutant thereof
#1102Methods of cell culture
#1103METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING COBALT
#1104Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
#1105Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor
#1106Anti-epidermal growth factor receptor (EGFR) antibodies
#1107Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#1108Immunoglobulin constant region Fc receptor binding agents
#1109TANDEM FC BISPECIFIC ANTIBODIES
#1110Fucosylation-deficient cells
#1111Antibodies that recognize red blood cell antigens
#1112Bispecific HER2 and CD3 binding molecules
#1113ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#1114ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
#1115Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
#1116METHODS TO CONTROL PROTEIN HETEROGENEITY
#1117Human immunodeficiency virus neutralizing antibodies
#1118COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
#1119Anti-HER3 antibodies and uses thereof
#1120Single-Arm Monovalent Antibody Constructs and Uses Thereof
#1121Combination therapies with anti-CD38 antibodies
#1122ANTIBODY FORMULATION
#1123Site-specific antibody-drug glycoconjugates and methods
#1124Oligosaccharide modification and labeling of proteins
#1125Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
#1126METHOD FOR MODULATING GALACTOSYLATION OF RECOMBINANT PROTEIN THROUGH OPTIMIZATION OF CULTURE MEDIUM
#1127NOVEL IMMUNOGLOBULIN VARIANTS
#1128Antibody variants composition
#1129Humanized antibodies against CD269 (BCMA)
#1130Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
#1131LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
#1132USE OF METAL IONS FOR MODULATION OF PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEINS
#1133Methods for producing recombinant glycoproteins with modified glycosylation
#1134FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
#1135CD80 extracellular domain polypeptides and their use in cancer treatment
#1136METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING MONOSACCHARIDES AND OLIGOSACCHARIDES
#1137Therapeutic antibodies
#1138Dosage and administration of non-fucosylated anti-CD40 antibodies
#1139Antibody purification and purity monitoring
#1140METHODS TO CONTROL PROTEIN HETEROGENEITY
#1141Interleukin-2 muteins for the expansion of T-regulatory cells
#1142Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferase
#1143ALPHA-V BETA-8 ANTIBODIES
#1144Human cytomegalovirus neutralizing antibodies and use thereof
#1145Human cytomegalovirus neutralizing antibodies and use thereof
#1146Antibody neutralizing human respiratory syncytial virus
#1147MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF
#1148Methods and compositions for treating systemic mastocytosis
#1149Bispecific antibodies specific for PD1 and TIM3
#1150TEM8 ANTIBODIES AND METHODS OF USE
#1151VEGF-A-BINDING PROTEINS AND HER2-BINDING PROTEINS WITH ENHANCED STABILITY AGAINST AGGREGATION
#1152A-fucosylation detection in antibodies
#1153CELL CULTURE PROCESS FOR PRODUCING A PROTEIN
#1154Method for preparing antibody through regulation of sugar content of antibody
#1155Homogenous antibody drug conjugates via enzymatic methods
#1156Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation
#1157ANTI-BLYS ANTIBODIES
#1158Anti-Blys antibody formulations and methods of treatment using them
#1159Methods for increasing mannose content of recombinant proteins
#1160Immunoconjugates
#1161Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#1162Polyomavirus neutralizing antibodies
#1163Multimeric Fc proteins
#1164Personalized production of biologics and method for reprogramming somatic cells
#1165MULTIMERIC FC PROTEINS
#1166Interleukin-2 muteins for the expansion of T-regulatory cells
#1167Composition that relieves heartburn, GERD and hangovers
#1168MODULATION OF CELL GROWTH AND GLYCOSYLATION IN RECOMBINANT GLYCOPROTEIN PRODUCTION
#1169Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
#1170PD-L1 antibodies
#1171Engineered antibody FC variants
#1172Anti-transthyretin antibodies
#1173Combination IL-2 immunoconjugate therapy
#1174METHODS TO PRODUCE SINGLE GLYCOFORM ANTIBODIES
#1175Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
#1176METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS
#1177Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75
#1178Antibodies, antibody drug conjugates and methods of use
#1179Methods of inhibition of protein fucosylation in vivo using fucose analogs
#1180Bispecific HER2 antibodies and methods of use
#1181COMPOSITIONS AND METHODS FOR USE IN ORGAN TRANSPLANTATION
#1182Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof
#1183METHOD OF INHIBITION OF LEUKEMIC STEM CELLS
#1184Prolactin receptor binding proteins and uses thereof
#1185Anti-Aβ globulomer 4D10 antibodies
#1186Anti-transthyretin antibodies
#1187PROCESS FOR THE ATTACHMENT OF A GALNAC MOIETY COMPRISING A (HETERO)ARYL GROUP TO A GLCNAC MOIETY, AND PRODUCT OBTAINED THEREBY
#1188METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
#1189FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#1190O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof
#1191Tight-binding agents and uses thereof
#1192Methods of producing anti-C5a antibodies
#1193Fc-ENHANCED ANTI-WT1/HLA ANTIBODY
#1194Anti-CLL-1 antibodies and methods of use
#1195Anti-CTLA-4 antibodies and methods of use thereof
#1196Compositions comprising antibodies to LINGO or fragments thereof
#1197Variant target binding agents and uses thereof
#1198Process for modifying galactosylation and GF content of a glycoprotein composition by glutamine supplementation
#1199Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
#1200Antagonists of IL-6 to raise albumin and/or lower CRP